| Name | Title | Contact Details |
|---|
XSELL Technologies is transforming the way businesses interact with their customers to build more meaningful relationships. We leverage augmented intelligence to deliver digital personalization at scale. Our unique business model brings together proprietary cloud-based natural language processing with deep human expertise to empower the best real-time responses to exponentially increase sales and conversion rates alongside an unmatched customer service experience. The power law in performance describes how 80% of a company`s results are produced by 20% of their workforce. Bringing our core belief to life required us to identify all of the behaviors of these top performers that enabled them to produce disproportionate results. These small groups of highly impactful employees often have specialized industry skill sets that translate into big results. And then deliver that top performer skillset with precision at scale, to the rest of the enterprise, driving game-changing outcomes by upskilling 80% of the workforce. To do this, we leverage artificial intelligence as a foundational capability to listen, learn and support agents in real time with the exact information they need to exceed customers expectations and deliver top performer experiences.
Azerion is a high-growth digital entertainment and media platform. As a content-driven, technology and data company, Azerion serves consumers, digital publishers, advertisers, and game creators globally.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
We enable health systems to communicate and collaborate more effectively through the use of our patient-centric mobile app, available on iOS and Android.
The Workgrid Assistant streamlines your day with an integrated view of tasks, approvals, reminders, and communications, so you can get more done, faster